

To:

Head of Paediatric Medicines
European Medicines Agency
30 Churchill Place
London E14 5EU
United Kingdom
paediatrics@ema.europa.eu

Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision

Actives substances(s): 17 beta-estradiol / etonogestrel

Invented name: N/A

Latest Decision number(s): 1) P/0028/2016 2) P/ 3) P/ 4) P/

Corresponding PIP number(s): 1) EMEA-001718-PIP01-14 2) EMEA- 3) EMEA- 4)
EMEA-

Please note that development of the medicinal product above in the [condition(s)/indication(s)]:

Treatment of dysmenorrhea and Prevention of pregnancy

☒ has been discontinued

☐ has been suspended/put on long-term hold (with possible re-start at a later time)

for the following reason(s): (tick all that apply)

☐ (possible) lack of efficacy in adults

☐ (possible) lack of efficacy in children

☐ (possible) unsatisfactory safety profile in adults

☐ (possible) unsatisfactory safety profile in children

☒ commercial reasons (please specify:)

☐ manufacturing / quality problems

☐ other regulatory action (please specify:) (e.g. suspension, revocation of M.A.)

☐ other reason (please specify:)

Please add a brief description (max 2000 characters) of the reason(s) for the discontinuation / suspension:

MSD has made a decision, based on business reasons only, to discontinue the clinical development program for the ENG-E2 vaginal ring, and therefore to discontinue all studies of the ENG-E2 vaginal ring. The decision not to continue the development of ENG-E2 vaginal ring was not due to safety or efficacy concerns.

Name and signature of the PIP contact point: signature on file

Date: 13 July 2016

Contact for inquiries from interested parties: Merck Sharp & Dohme (Europe), Inc.

Telephone:

+33 180 464 738

Email:

pip.information@merck.com